SCHEMBL18969702

SCHEMBL18969702

Cc1ccc2c(c1)c(C)c(C)n2-c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.48
GFER P55789 1/20 0.48
HPGD P15428 3/20 0.47
HTT P42858 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
LMNA P02545 2/20 0.47
MAPT P10636 5/20 0.44
KDM4E B2RXH2 4/20 0.44
HSD17B10 Q99714 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
PKM P14618 1/20 0.44
ALOX15 P16050 1/20 0.44
CYP2C19 P33261 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
ATM Q13315 1/20 0.44
FGFR1 P11362 1/20 0.42
KMT2A Q03164 6/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL679015 0.85 KDM4E (0.56) GAAGFERHPGDHTTSMN1; SMN2
SCHEMBL17906224 0.83 GAA (0.46) GAAGFERHPGDHTTSMN1; SMN2
SCHEMBL6940379 0.81 KDM4E (0.52) GAAGFERHPGDHTTSMN1; SMN2
SCHEMBL11379057 0.81 KDM4E (0.61) GAAGFERHPGDHTTSMN1; SMN2
SCHEMBL17617920 0.80 KDM4E (0.50) GAAGFERHPGDHTTSMN1; SMN2
SCHEMBL21515583 0.80 KDM4E (0.50) GAAGFERHPGDHTTSMN1; SMN2
SCHEMBL262331 0.80 KDM4E (0.67) GAAGFERHPGDHTTSMN1; SMN2
SCHEMBL21515581 0.80 KDM4E (0.50) GAAGFERHPGDHTTSMN1; SMN2
SCHEMBL31373788 0.80 KDM4E (0.67) GAAGFERHPGDHTTSMN1; SMN2
SCHEMBL26570029 0.80 KDM4E (0.50) GAAGFERHPGDHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10297755-B2 Oxygen substituted benzoclobutenes derived compositions for electronic devices DOW GLOBAL TECHNOLOGIES LLC (US) 2019-05-21 US disclosed
US-9966537-B2 Compositions with 2,3-disubstituted indoles as charge transport materials, and display devices fabricated therefrom DOW GLOBAL TECHNOLOGIES LLC (US) 2018-05-08 US disclosed
US-9966537-B2 Compositions with 2,3-disubstituted indoles as charge transport materials, and display devices fabricated therefrom DOW GLOBAL TECHNOLOGIES LLC (US) 2018-05-08 US disclosed
US-20170373253-A1 Compositions with 2,3-Disubstituted Indoles as Charge Transport Materials, and Display Devices Fabricated Therefrom DOW GLOBAL TECHNOLOGIES LLC 2017-12-28 US disclosed
US-20170170398-A1 OXYGEN SUBSTITUTED BENZOCLOBUTENES DERIVED COMPOSITIONS FOR ELECTRONIC DEVICES DOW GLOBAL TECHNOLOGIES LLC (US) 2017-06-15 US disclosed
US-20170170398-A1 OXYGEN SUBSTITUTED BENZOCLOBUTENES DERIVED COMPOSITIONS FOR ELECTRONIC DEVICES DOW GLOBAL TECHNOLOGIES LLC (US) 2017-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170373253-A1 Compositions with 2,3-Disubstituted Indoles as Charge Transport Materials, and Display Devices Fabricated Therefrom IDO2, HTR3D, IDO1 GAA 4608/4885GFER 3389/4885HPGD 3213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.